Literature DB >> 17612630

The artificial 4-zinc-finger protein Bagly binds human utrophin promoter A at the endogenous chromosomal site and activates transcription.

Annalisa Onori1, Agata Desantis, Serena Buontempo, Maria Grazia Di Certo, Maurizio Fanciulli, Luisa Salvatori, Claudio Passananti, Nicoletta Corbi.   

Abstract

Our aim is to upregulate the expression of the dystrophin-related gene utrophin in Duchenne muscular dystrophy, in this way complementing the lack of dystrophin function. To achieve utrophin upregulation, we designed and engineered synthetic zinc-finger based transcription factors. We have previously shown that the artificial 3-zinc-finger protein Jazz, fused with the appropriate effector domain, is able to drive the transcription of a test gene from utrophin promoter A. Here we report a novel artificial 4-zinc-finger protein, Bagly, which binds with optimized affinity-specificity to a 12 bp DNA target sequence that is internal to human utrophin promoter A. Bagly was generated adding to Jazz protein an extra-fourth zinc finger, derived from transcription factor YY1. Importantly, the Bagly DNA target sequence is statistically present in the human genome only 210 times, about 60 fewer times than the 9 bp Jazz DNA target sequence. Thanks to its additional zinc-finger domain, Bagly protein shows enhanced transcriptional activity. Moreover, we demonstrated Bagly's effective access and binding to active chromatin in the chromosomal context and its ability to upregulate endogenous utrophin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17612630     DOI: 10.1139/o07-015

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  7 in total

1.  Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors.

Authors:  Christian Huisman; G Bea A Wisman; Hinke G Kazemier; Marcel A T M van Vugt; Ate G J van der Zee; Ed Schuuring; Marianne G Rots
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

Review 2.  Genome engineering: a new approach to gene therapy for neuromuscular disorders.

Authors:  Christopher E Nelson; Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Nat Rev Neurol       Date:  2017-09-29       Impact factor: 42.937

Review 3.  High throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomics.

Authors:  Thomas J J Gintjee; Alvin S H Magh; Carmen Bertoni
Journal:  Biology (Basel)       Date:  2014-11-14

4.  UtroUp is a novel six zinc finger artificial transcription factor that recognises 18 base pairs of the utrophin promoter and efficiently drives utrophin upregulation.

Authors:  Annalisa Onori; Cinzia Pisani; Georgios Strimpakos; Lucia Monaco; Elisabetta Mattei; Claudio Passananti; Nicoletta Corbi
Journal:  BMC Mol Biol       Date:  2013-01-30       Impact factor: 2.946

5.  Utrophin up-regulation by an artificial transcription factor in transgenic mice.

Authors:  Elisabetta Mattei; Nicoletta Corbi; Maria Grazia Di Certo; Georgios Strimpakos; Cinzia Severini; Annalisa Onori; Agata Desantis; Valentina Libri; Serena Buontempo; Aristide Floridi; Maurizio Fanciulli; Dilair Baban; Kay E Davies; Claudio Passananti
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

6.  Novel adeno-associated viral vector delivering the utrophin gene regulator jazz counteracts dystrophic pathology in mdx mice.

Authors:  Georgios Strimpakos; Nicoletta Corbi; Cinzia Pisani; Maria Grazia Di Certo; Annalisa Onori; Siro Luvisetto; Cinzia Severini; Francesca Gabanella; Lucia Monaco; Elisabetta Mattei; Claudio Passananti
Journal:  J Cell Physiol       Date:  2014-09       Impact factor: 6.384

7.  Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies.

Authors:  Patricia Soblechero-Martín; Andrea López-Martínez; Laura de la Puente-Ovejero; Ainara Vallejo-Illarramendi; Virginia Arechavala-Gomeza
Journal:  Neuropathol Appl Neurobiol       Date:  2021-06-04       Impact factor: 8.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.